Stanford Cancer Institute

Gastrointestinal

Colorectal

Metastatic

1st Line

GI0022 Phase Ib/II Targeted Therapies in Subpopulations with Metastatic Colorectal Cancer (INTRINSIC)
P: Fisher Stanford

COR0021 Phase II TATE (Trans-Arterial Tirapazamine Embolization) +/- Pembrolizumab in Liver mCRC and NSCLC
P: Heestand Tecilson Limited

ECOG-ACRIN A021703 Phase III Vitamin D3 Supplementation in Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
P: Fisher Stanford

GI0021 Phase 1b Tucatinib in Combo w/ Trastuzumab & Oxaliplatin-Based Chemotherapy in HER2+ GI Cancers
P: Chen Sponsor: Seattle Genetics

Locally Advanced

2nd Line

COR0020 MOUNTAINEER: Phase II Tucatinib Combined w/ Trastuzumab in HER2+ Metastatic Colorectal Cancer
P: Chen Pending

COR0018: Phase II Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
P: Pollock Stanford

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
TrialPosting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu